Bank of America’s Regenxbio RGNX Stock Holding History

Bank of America’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-30,000	Closed	-$741K	–	8130
2022 Q2	$741K	Hold	30,000	–	–	﹤0.01%	5160
2022 Q1	$996K	Buy	+30,000	New	+$833K	﹤0.01%	5262
2020 Q1	–	Sell	-30,000	Closed	-$1.23M	–	7182
2019 Q4	$1.23M	Buy	+30,000	New	+$1.19M	﹤0.01%	4360
2018 Q1	–	Sell	-33,500	Closed	-$1.11M	–	7304
2017 Q4	$1.11M	Buy	+33,500	New	+$1.01M	﹤0.01%	4413

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America's RGNX Position: Q1 2026 in Review

Bank of America increased its Regenxbio (RGNX) stake by 8.1% in Q1 2026, buying an estimated $255K and bringing the position to 324,860 shares worth $2.72M. The position accounts for ﹤0.01% of the portfolio, ranked #3902.

Bank of America first reported a position in RGNX in Q3 2015 and has held it in 43 quarters since. The position peaked at $5.85M in Q1 2022. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

Bank of America held 324,860 shares of Regenxbio worth $2.72M as of Q1 2026.
Bank of America bought 24,251 Regenxbio shares in Q1 2026, an estimated $255K.
Regenxbio made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3902 holding.
Bank of America first reported a position in Regenxbio in Q3 2015 and has held it in 43 quarters since.
Bank of America's Regenxbio position peaked at $5.85M in Q1 2022.
178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.